{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:45:31Z","timestamp":1792140331942,"version":"4.4.0"},"reference-count":291,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118532","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:41:28Z","timestamp":1791848488000},"page":"118532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["Protein degraders targeting JAK\/STAT3 signaling pathway are emerging therapeutic modalities for human cancers"],"prefix":"10.1016","volume":"254","author":[{"given":"Xinyu","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingling","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoquan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-0883","authenticated-orcid":false,"given":"Zhu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0010","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.cellsig.2013.05.007","article-title":"Regulation of STAT signaling by acetylation","volume":"25","author":"Zhuang","year":"2013","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118532_b0020","doi-asserted-by":"crossref","unstructured":"H.Q. Wang, Q.W. Man, F.Y. Huo, X. Gao, H. Lin, S.R. Li, J. Wang, F.C. Su, L. Cai, Y. Shi, B. Liu, L.L. Bu, STAT3 pathway in cancers: Past, present, and future, MedComm (2020) 3(2) (2022) e124.","DOI":"10.1002\/mco2.124"},{"key":"10.1016\/j.bcp.2026.118532_b0025","article-title":"The effects of STAT3 acetylation on the transcriptional activity and tumorigenesis","volume":"117076","author":"Yan","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.tips.2024.07.003","article-title":"Targeting the STAT3 pathway with STAT3 degraders","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/13543784.2021.1891222","article-title":"An update on investigational therapies that target STAT3 for the treatment of cancer","volume":"30","author":"Santoni","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0040","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41388-020-01626-z","article-title":"Targeting STAT3 by a small molecule suppresses pancreatic cancer progression","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.bcp.2026.118532_b0045","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-22-0744","article-title":"STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer","volume":"28","author":"Qureshy","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0050","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/cas.15761","article-title":"STAT3 regulates 5-Fu resistance in human colorectal cancer cells by promoting Mcl-1-dependent cytoprotective autophagy","volume":"114","author":"Yue","year":"2023","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in Cancer Immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189207","article-title":"Structure, function, signaling pathways and clinical therapeutics: the translational potential of STAT3 as a target for cancer therapy","volume":"1879","author":"Shi","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"314","key":"10.1016\/j.bcp.2026.118532_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0070","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant Durvalumab Alone or combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: the phase II NeoCOAST Platform Trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055718","volume":"12","author":"Nishina","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.bcp.2026.118532_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcancer.2019.09.022","article-title":"Repurposing of drugs as STAT3 inhibitors for cancer therapy","volume":"68","author":"Thilakasiri","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"17","key":"10.1016\/j.bcp.2026.118532_b0085","doi-asserted-by":"crossref","first-page":"12373","DOI":"10.1021\/acs.jmedchem.3c00863","article-title":"Discovery, Optimization, and Evaluation of Novel N-(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine Analogues as Potent STAT3 Inhibitors for Cancer Treatment","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0090","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41401-024-01261-4","article-title":"Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma","volume":"45","author":"Zhang","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"13","key":"10.1016\/j.bcp.2026.118532_b0095","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","article-title":"Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: from Phosphorylation Inhibition to Protein Degradation","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202501111","article-title":"Insights into Vepdegestrant (ARV-471): the First-in-Class Estrogen Receptor Proteolysis-Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer","volume":"21","author":"Tang","year":"2026","journal-title":"ChemMedChem"},{"issue":"14","key":"10.1016\/j.bcp.2026.118532_b0105","doi-asserted-by":"crossref","first-page":"16135","DOI":"10.1021\/acs.jmedchem.6c02076","article-title":"FDA Approval of the First-ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation","volume":"69","author":"Kumar","year":"2026","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics18070827","article-title":"From Concept to Clinic: Vepdegestrant (ARV 471) Becomes the first Approved PROTAC Drug","volume":"18","author":"Bege","year":"2026","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"13","key":"10.1016\/j.bcp.2026.118532_b0120","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6168","key":"10.1016\/j.bcp.2026.118532_b0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"7559","key":"10.1016\/j.bcp.2026.118532_b0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"issue":"7512","key":"10.1016\/j.bcp.2026.118532_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010217","article-title":"Role of JAK\/STAT3 Signaling in the Regulation of Metastasis, the transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal transition","volume":"9","author":"Jin","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0145","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.bcp.2006.04.013","article-title":"Jaks and cytokine receptors\u2013an intimate relationship","volume":"72","author":"Haan","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J"},{"key":"10.1016\/j.bcp.2026.118532_b0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fendo.2017.00071","article-title":"The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions","volume":"8","author":"Ferrao","year":"2017","journal-title":"Front Endocrinol (lausanne)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051001","article-title":"A Comprehensive Overview of Globally Approved JAK Inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"Pt 11","key":"10.1016\/j.bcp.2026.118532_b0170","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1107\/S2053230X16016356","article-title":"Development of a high-throughput crystal structure-determination platform for JAK1 using a novel metal-chelator soaking system","volume":"72","author":"Caspers","year":"2016","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"issue":"23","key":"10.1016\/j.bcp.2026.118532_b0175","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b0180","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"19","key":"10.1016\/j.bcp.2026.118532_b0185","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0190","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1038\/s41467-020-17920-z","article-title":"Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains","volume":"11","author":"La Sala","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41419-024-06749-9","article-title":"A novel function of STAT3beta in suppressing interferon response improves outcome in acute myeloid leukemia","volume":"15","author":"Edtmayer","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v5.i2.231","article-title":"Regulation and function of signal transducer and activator of transcription 3","volume":"5","author":"Qi","year":"2014","journal-title":"World J. Biol. Chem."},{"issue":"472","key":"10.1016\/j.bcp.2026.118532_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aag2588","article-title":"Stress-induced dynamic regulation of mitochondrial STAT3 and its association with cyclophilin D reduce mitochondrial ROS production","volume":"10","author":"Meier","year":"2017","journal-title":"Sci. Signal."},{"issue":"43","key":"10.1016\/j.bcp.2026.118532_b0210","doi-asserted-by":"crossref","first-page":"31280","DOI":"10.1074\/jbc.M113.505057","article-title":"Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727","volume":"288","author":"Zhang","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b0215","doi-asserted-by":"crossref","first-page":"976","DOI":"10.7150\/thno.63751","article-title":"Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118532_b0220","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fcell.2020.00274","article-title":"STAT3 Localizes in Mitochondria-Associated ER Membranes instead of in Mitochondria","volume":"8","author":"Su","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080956","article-title":"The Roles of Post-Translational modifications in STAT3 Biological Activities and Functions","volume":"9","author":"Tesoriere","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118532_b0230","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ejmech.2018.08.037","article-title":"Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis","volume":"157","author":"Huang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"48","key":"10.1016\/j.bcp.2026.118532_b0235","doi-asserted-by":"crossref","first-page":"14811","DOI":"10.1073\/pnas.1515876112","article-title":"Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity","volume":"112","author":"Mertens","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118532_b0240","doi-asserted-by":"crossref","unstructured":"L. Bai, H. Zhou, R. Xu, Y. Zhao, K. Chinnaswamy, D. McEachern, J. Chen, C.Y. Yang, Z. Liu, M. Wang, L. Liu, H. Jiang, B. Wen, P. Kumar, J.L. Meagher, D. Sun, J.A. Stuckey, S. Wang, A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo, Cancer Cell 36(5) (2019) 498-511 e17.","DOI":"10.1016\/j.ccell.2019.10.002"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188574","article-title":"Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma","volume":"1876","author":"Mohan","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170390","article-title":"The G Protein-coupled Receptor RAI3 is an Independent Prognostic factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation","volume":"12","author":"Jahny","year":"2017","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.bcp.2026.118532_b0255","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.7150\/thno.44417","article-title":"Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma","volume":"10","author":"Zhou","year":"2020","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b0260","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/ijc.32060","article-title":"Toll-like receptor 2 regulates metabolic reprogramming in gastric cancer via superoxide dismutase 2","volume":"144","author":"Liu","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0265","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.gendis.2021.04.003","article-title":"Targeting LIF\/LIFR signaling in cancer","volume":"9","author":"Viswanadhapalli","year":"2022","journal-title":"Genes Dis"},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0270","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","article-title":"STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis","volume":"69","author":"Heichler","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0275","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0280","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.bcp.2026.118532_b0285","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b0290","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol. Cell. Proteomics"},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b0295","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"issue":"57","key":"10.1016\/j.bcp.2026.118532_b0300","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1038\/onc.2008.320","article-title":"Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer","volume":"27","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Oncogene"},{"issue":"17","key":"10.1016\/j.bcp.2026.118532_b0305","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/cbic.200700438","article-title":"Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool","volume":"8","author":"Lee","year":"2007","journal-title":"Chembiochem"},{"issue":"22","key":"10.1016\/j.bcp.2026.118532_b0310","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"16","key":"10.1016\/j.bcp.2026.118532_b0315","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1021\/ja100691p","article-title":"Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins","volume":"132","author":"Itoh","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"5971","key":"10.1016\/j.bcp.2026.118532_b0320","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"46","key":"10.1016\/j.bcp.2026.118532_b0325","doi-asserted-by":"crossref","first-page":"11463","DOI":"10.1002\/anie.201206231","article-title":"Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1alpha","volume":"51","author":"Buckley","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"6168","key":"10.1016\/j.bcp.2026.118532_b0330","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"6241","key":"10.1016\/j.bcp.2026.118532_b0335","first-page":"1376","article-title":"DRUG DEVELOPMENT","volume":"348","author":"Winter","year":"2015","journal-title":"Phthalimide Conjugation as a Strategy for in Vivo Target Protein Degradation, Science"},{"issue":"6414","key":"10.1016\/j.bcp.2026.118532_b0340","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b0345","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1alpha interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"22","key":"10.1016\/j.bcp.2026.118532_b0350","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1073\/pnas.1217206110","article-title":"Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs","volume":"110","author":"Hines","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0355","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0360","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0365","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","article-title":"Homo-PROTACs for the Chemical Knockdown of Cereblon","volume":"13","author":"Steinebach","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0370","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"Trauner, PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0375","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5154","article-title":"Light-induced control of protein destruction by opto-PROTAC","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"issue":"46","key":"10.1016\/j.bcp.2026.118532_b0380","doi-asserted-by":"crossref","first-page":"18370","DOI":"10.1021\/jacs.9b06422","article-title":"Light-Induced Protein Degradation with Photocaged PROTACs","volume":"141","author":"Xue","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0385","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/anie.202012330","article-title":"RNA-PROTACs: Degraders of RNA-Binding Proteins","volume":"60","author":"Ghidini","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b0390","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0395","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41573-023-00652-2","article-title":"Delivering on the promise of protein degraders","volume":"22","author":"O'Brien Laramy","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Pt 2","key":"10.1016\/j.bcp.2026.118532_b0400","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","article-title":"PROTACs: a novel strategy for cancer therapy","volume":"67","author":"Liu","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2026.118532_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115444","article-title":"Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design","volume":"256","author":"Mi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b0410","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0415","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.tibs.2017.09.002","article-title":"The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy","volume":"42","author":"Kwon","year":"2017","journal-title":"Trends Biochem. Sci"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0420","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0425","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin-proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0430","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrd2056","article-title":"Drug discovery in the ubiquitin-proteasome system","volume":"5","author":"Nalepa","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0435","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ncb3358","article-title":"The increasing complexity of the ubiquitin code","volume":"18","author":"Yau","year":"2016","journal-title":"Nat. Cell Biol."},{"issue":"22","key":"10.1016\/j.bcp.2026.118532_b0440","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.7150\/thno.46985","article-title":"The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination","volume":"10","author":"Jin","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118532_b0445","doi-asserted-by":"crossref","unstructured":"K.T.G. Samarasinghe, S. Jaime-Figueroa, M. Burgess, D.A. Nalawansha, K. Dai, Z. Hu, A. Bebenek, S.A. Holley, C.M. Crews, Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras, Cell Chem Biol 28(5) (2021) 648-661 e5.","DOI":"10.1016\/j.chembiol.2021.03.011"},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0450","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an Emerging Therapeutic Modality in Precision Medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b0455","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118532_b0460","article-title":"Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism","volume":"4","author":"Lu","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2026.118532_b0465","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.672267","article-title":"From Conception to Development: investigating PROTACs Features for improved Cell Permeability and successful Protein Degradation","volume":"9","author":"Cecchini","year":"2021","journal-title":"Front. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0470","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","article-title":"Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)","volume":"61","author":"Powell","year":"2018","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0480","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/acsmedchemlett.0c00265","article-title":"Understanding and improving the Membrane Permeability of VH032-based PROTACs","volume":"11","author":"Klein","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0485","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/acs.jmedchem.7b00237","article-title":"How big is too big for Cell Permeability?","volume":"60","author":"Matsson","year":"2017","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bcp.2026.118532_b0490","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1021\/jacs.1c03852","article-title":"TF-PROTACs Enable Targeted Degradation of Transcription Factors","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0495","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6702","key":"10.1016\/j.bcp.2026.118532_b0500","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0505","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1021\/acs.jmedchem.2c01115","article-title":"Design, Synthesis, and Biological activity of Marinacarboline Analogues as STAT3 Pathway Inhibitors for Docetaxel-Resistant Triple-negative Breast Cancer","volume":"66","author":"Byun","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0510","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.4081\/oncol.2012.e13","article-title":"Janus kinase inhibitors: jackpot or potluck?","volume":"6","author":"Pavithran","year":"2012","journal-title":"Oncol. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0515","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0520","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4155\/fmc-2021-0324","article-title":"Proteolysis-targeting chimera molecules targeting SHP2","volume":"14","author":"Yu","year":"2022","journal-title":"Future Med. Chem."},{"issue":"14","key":"10.1016\/j.bcp.2026.118532_b0525","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, Potent, and Effective PROTAC Degrader of SHP2 Protein","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2026.118532_b0530","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118532_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118532_b0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"Kerr","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0545","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1128\/MCB.19.3.2416","article-title":"Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak\/STAT pathway","volume":"19","author":"You","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"42","key":"10.1016\/j.bcp.2026.118532_b0550","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1038\/sj.onc.1204699","article-title":"The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase\/Akt activation by growth factors","volume":"20","author":"Wu","year":"2001","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0555","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0560","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b0565","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.M513068200","article-title":"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects","volume":"281","author":"Kontaridis","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b0570","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat. Genet."},{"issue":"24","key":"10.1016\/j.bcp.2026.118532_b0575","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires-Alj","year":"2004","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b0580","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer Metastasis Rev."},{"issue":"25","key":"10.1016\/j.bcp.2026.118532_b0585","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1038\/sj.onc.1211019","article-title":"Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors","volume":"27","author":"Miyamoto","year":"2008","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0590","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nm.2645","article-title":"Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop","volume":"18","author":"Aceto","year":"2012","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0595","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.bcp.2026.118532_b0600","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1021\/jm010266w","article-title":"Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics","volume":"44","author":"Jia","year":"2001","journal-title":"J. Med. Chem."},{"issue":"35","key":"10.1016\/j.bcp.2026.118532_b0605","doi-asserted-by":"crossref","first-page":"30984","DOI":"10.1074\/jbc.M504699200","article-title":"Diverse biochemical properties of Shp2 mutants","volume":"280","author":"Keilhack","year":"2005","journal-title":"Implications for Disease Phenotypes, J Biol Chem"},{"key":"10.1016\/j.bcp.2026.118532_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104788","article-title":"Novel PROTACs for degradation of SHP2 protein","volume":"110","author":"Zheng","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"7610","key":"10.1016\/j.bcp.2026.118532_b0615","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.bcp.2026.118532_b0620","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bcp.2026.118532_b0625","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bcp.2026.118532_b0630","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-24-3691","article-title":"JAB-3312, a Potent Allosteric SHP2 Inhibitor that Enhances the Efficacy of RTK\/RAS\/MAPK and PD-1 Blockade Therapies","volume":"31","author":"Kang","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0635","article-title":"Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML","volume":"4","author":"Popescu","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0640","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0645","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nat. Med."},{"issue":"34","key":"10.1016\/j.bcp.2026.118532_b0650","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.biochem.1c00377","article-title":"Targeted Degradation of the Oncogenic Phosphatase SHP2","volume":"60","author":"Vemulapalli","year":"2021","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107616","article-title":"Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2","volume":"300","author":"Hoffman","year":"2024","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0660","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1073\/pnas.1920251117","article-title":"bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)","volume":"117","author":"Lim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105381","article-title":"Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach","volume":"299","author":"VanDyke","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0670","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543776.2025.2477486","article-title":"Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022\u20132023)","volume":"35","author":"Shah","year":"2025","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2026.118532_b0675","doi-asserted-by":"crossref","unstructured":"M.L. Arwood, Y. Liu, S.K. Harkins, D.M. Weinstock, L. Yang, K.E. Stevenson, O.D. Plana, J. Dong, H. Cirka, K.L. Jones, A.T. Virtanen, D.G. Gupta, A. Ceas, B. Lawney, A. Yoda, C. Leahy, M. Hao, Z. He, H.G. Choi, Y. Wang, O. Silvennoinen, S.R. Hubbard, T. Zhang, N.S. Gray, L.S. Li, New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation, Cell Chem Biol 30(6) (2023) 618-631 e12.","DOI":"10.1016\/j.chembiol.2023.05.007"},{"key":"10.1016\/j.bcp.2026.118532_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129838","article-title":"Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities","volume":"109","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0685","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b0690","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0695","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0700","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a Type II JAK2 Inhibitor, reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0705","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"48","key":"10.1016\/j.bcp.2026.118532_b0715","first-page":"32297","article-title":"Conditional activation of Janus kinase (JAK) confers factor independence upon interleukin-3-dependent cells","volume":"273","author":"Mizuguchi","year":"1998","journal-title":"Essential Role of Ras in JAK-Triggered Mitogenesis, J Biol Chem"},{"key":"10.1016\/j.bcp.2026.118532_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116167","article-title":"JAK1\/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118532_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129083","article-title":"Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor","volume":"79","author":"Kato","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0730","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/acsmedchemlett.1c00650","article-title":"Development of Potent and Selective Janus Kinase 2\/3 Directing PG-PROTACs","volume":"13","author":"Alcock","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.bcp.2026.118532_b0735","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/imt-2021-0096","article-title":"TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases","volume":"13","author":"Gonciarz","year":"2021","journal-title":"Immunotherapy"},{"issue":"7848","key":"10.1016\/j.bcp.2026.118532_b0740","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","article-title":"Genetic mechanisms of critical illness in COVID-19","volume":"591","author":"Pairo-Castineira","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118532_b0745","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cyto.2015.10.015","article-title":"Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene","volume":"89","author":"Leitner","year":"2017","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0750","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/13543776.2022.2026927","article-title":"Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021)","volume":"32","author":"F. Gonzalez Lopez de Turiso, K. Guckian,","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"issue":"20","key":"10.1016\/j.bcp.2026.118532_b0755","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b0760","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/acs.jmedchem.0c01468","article-title":"Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0765","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: a Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0770","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b0775","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4049\/immunohorizons.2000108","article-title":"Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides","volume":"5","author":"Tran","year":"2021","journal-title":"Immunohorizons"},{"issue":"26","key":"10.1016\/j.bcp.2026.118532_b0780","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1200\/JCO.2008.21.3264","article-title":"Targeting signal transducer and activator of transcription signaling pathway in leukemias","volume":"27","author":"Benekli","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"49","key":"10.1016\/j.bcp.2026.118532_b0785","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0790","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.bcp.2026.118532_b0795","article-title":"Kill two Birds with one Stone: a Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-positive Leukemia","volume":"9","author":"Ma","year":"2022","journal-title":"Adv Sci (weinh)"},{"issue":"20","key":"10.1016\/j.bcp.2026.118532_b0800","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0805","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41375-024-02365-w","article-title":"BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): the new frontier in the treatment of Ph(+) leukemias?","volume":"38","author":"Cruz-Rodriguez","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b0810","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"50","key":"10.1016\/j.bcp.2026.118532_b0815","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1039\/D0CC02201B","article-title":"Scaffold hopping enables direct access to more potent PROTACs with in vivo activity","volume":"56","author":"Burslem","year":"2020","journal-title":"Chem. Commun. (Camb)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0820","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071671","article-title":"A Review of the Current Impact of Inhibitors of Apoptosis Proteins and their repression in Cancer","volume":"14","author":"Cetraro","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.bcp.2026.118532_b0825","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.bmcl.2016.09.041","article-title":"Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand","volume":"26","author":"Demizu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0830","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b0835","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","article-title":"Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0840","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0845","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.molcel.2022.02.004","article-title":"How the ends signal the end: Regulation by E3 ubiquitin ligases recognizing protein termini","volume":"82","author":"Sherpa","year":"2022","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104994","article-title":"Single amino acid-based PROTACs trigger degradation of the oncogenic kinase BCR-ABL in chronic myeloid leukemia (CML)","volume":"299","author":"Zhang","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.bcp.2026.118532_b0855","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1101\/gad.9.21.2583","article-title":"Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity","volume":"9","author":"Shi","year":"1995","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0860","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/35073094","article-title":"The hunting of the Src","volume":"2","author":"Martin","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0865","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/acschembio.3c00548","article-title":"Selective and Potent PROTAC Degraders of c-Src Kinase","volume":"19","author":"Mao","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0870","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2004.09.001","article-title":"c-Src and cooperating partners in human cancer","volume":"6","author":"Ishizawar","year":"2004","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0875","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162324","article-title":"Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression","volume":"133","author":"Nandi","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"678","key":"10.1016\/j.bcp.2026.118532_b0880","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7895","article-title":"Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models","volume":"15","author":"Su","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b0885","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ijc.23321","article-title":"Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi","volume":"122","author":"Zheng","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b0890","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdn291","article-title":"Targeting Src in breast cancer","volume":"19","author":"Finn","year":"2008","journal-title":"Ann. Oncol."},{"issue":"45","key":"10.1016\/j.bcp.2026.118532_b0895","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41388-022-02487-4","article-title":"Src: coordinating metabolism in cancer","volume":"41","author":"Pelaz","year":"2022","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b0900","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030462","article-title":"The Relevance of the SH2 Domain for c-Src Functionality in Triple-negative Breast Cancer Cells","volume":"13","author":"Mayoral-Varo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0905","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: New Approaches to Protein Degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"24","key":"10.1016\/j.bcp.2026.118532_b0910","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2026.118532_b0915","doi-asserted-by":"crossref","first-page":"8261","DOI":"10.1111\/jcmm.16754","article-title":"SD-36 promotes growth inhibition and induces apoptosis via suppression of Mcl-1 in glioma","volume":"25","author":"Kong","year":"2021","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b0920","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1021\/acsmedchemlett.1c00155","article-title":"SD-91 as a Potent and Selective STAT3 Degrader Capable of Achieving complete and Long-Lasting Tumor Regression","volume":"12","author":"Zhou","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"22","key":"10.1016\/j.bcp.2026.118532_b0925","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1021\/acs.jmedchem.4c01946","article-title":"Discovery of SD-436: a Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving complete and Long-Lasting Tumor Regression","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118532_b0930","article-title":"Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"47","key":"10.1016\/j.bcp.2026.118532_b0935","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1038\/onc.2017.270","article-title":"Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.bcp.2026.118532_b0940","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160606","article-title":"Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer","volume":"7","author":"Jin","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2026.118532_b0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117507","article-title":"Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3","volume":"95","author":"Shih","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118532_b0950","doi-asserted-by":"crossref","unstructured":"J. Hall, Z. Zhang, D. Wang, S. Bhattacharya, M. Alcantara, Y. Liang, P. Swiderski, S. Forman, L. Kwak, N. Vaidehi, M. Kortylewski, Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3, bioRxiv (2023).","DOI":"10.1101\/2023.08.01.551552"},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b0955","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1039\/D4MD00546E","article-title":"Hydrophobic CPP\/HDO conjugates: a new frontier in oligonucleotide-warheaded PROTAC delivery","volume":"15","author":"Naganuma","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0960","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1073\/pnas.0534764100","article-title":"Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth","volume":"100","author":"Leong","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102137","article-title":"Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3","volume":"35","author":"Hall","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bcp.2026.118532_b0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107686","article-title":"The strategies and techniques of drug discovery from natural products","volume":"216","author":"Zhang","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118532_b0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108833","article-title":"Recent advances in target identification technology of natural products","volume":"269","author":"Liu","year":"2025","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0980","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/s41467-021-22174-4","article-title":"Natural product fragment combination to performance-diverse pseudo-natural products","volume":"12","author":"Grigalunas","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b0985","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/cbdd.14231","article-title":"Current understanding and future prospects on Berberine for anticancer therapy","volume":"102","author":"Goel","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b0990","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1142\/S0192415X15500846","article-title":"Berberine increases Doxorubicin Sensitivity by Suppressing STAT3 in Lung Cancer","volume":"43","author":"Zhu","year":"2015","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.bcp.2026.118532_b0995","first-page":"5611","article-title":"Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway","volume":"9","author":"Nie","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b1000","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108824","article-title":"Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis","volume":"24","author":"Rocchetti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118532_b1005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.omto.2021.12.025","article-title":"Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells","volume":"24","author":"Lv","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bcp.2026.118532_b1010","first-page":"743","article-title":"Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3, Front","volume":"9","author":"Alsamri","year":"2019","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/jcpt.13039","article-title":"Application of capsaicin as a potential new therapeutic drug in human cancers","volume":"45","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s11671-025-04239-1","article-title":"The delivery carriers and applications for Xiaobojian","volume":"20","author":"Huang","year":"2025","journal-title":"Discov Nano"},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1025","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17030331","article-title":"In Vitro Evaluation of the Safety and Antineoplastic Effects in Gastrointestinal Tumors of Nanostructured Lipid Carriers Loaded with Berberine","volume":"17","author":"Stefanova","year":"2025","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/acs.jafc.1c06437","article-title":"Capsaicin Attenuates Oleic Acid-Induced Lipid Accumulation via the Regulation of Circadian Clock Genes in HepG2 Cells","volume":"70","author":"Li","year":"2022","journal-title":"J. Agric. Food Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b1035","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1038\/s41401-023-01111-9","article-title":"Capsaicin functions as a selective degrader of STAT3 to enhance host resistance to viral infection","volume":"44","author":"Zhang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b1040","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1002\/ptr.8213","article-title":"Carnosol prevents cardiac remodeling and ventricular arrhythmias in pressure overload-induced heart failure mice","volume":"38","author":"Fang","year":"2024","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b1045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15430\/JCP.2014.19.2.103","article-title":"Carnosol: a phenolic diterpene with cancer chemopreventive potential","volume":"19","author":"Chun","year":"2014","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.bcp.2026.118532_b1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108612","article-title":"Luteolin, a flavonoid, as an anticancer agent: a review","volume":"112","author":"Imran","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118532_b1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115044","article-title":"Luteolin binds Src, promotes STAT3 protein ubiquitination and exerts anti-melanoma effects in cell and mouse models","volume":"200","author":"Li","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b1060","article-title":"Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A\/Act1\/TRAF6\/NF-kappaB signaling pathway","volume":"11","author":"Deng","year":"2024","journal-title":"Genes Dis"},{"key":"10.1016\/j.bcp.2026.118532_b1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107452","article-title":"Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony","volume":"207","author":"Zhang","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118532_b1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154901","article-title":"Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy","volume":"116","author":"Cao","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2026.118532_b1075","doi-asserted-by":"crossref","unstructured":"S. Chakraborty, C. Morganti, B.R. Pena, H. Zhang, D. Verma, K. Zaldana, N. Gitego, F. Ma, S. Aluri, K. Pradhan, S. Gordon, I. Mantzaris, M. Goldfinger, E. Feldman, K. Gritsman, Y. Shi, S. Hubner, Y.H. Qiu, B.D. Brown, A. Skwarska, A. Verma, M. Konopleva, Y. Tabe, E. Gavathiotis, S. Colla, J. Gollob, J. Dey, S.M. Kornblau, S.B. Koralov, K. Ito, A. Shastri, A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia, bioRxiv (2024).","DOI":"10.1101\/2024.08.05.599788"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-025-01674-6","article-title":"Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2012.06.006","article-title":"STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma","volume":"325","author":"Tu","year":"2012","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b1090","doi-asserted-by":"crossref","first-page":"e2421","DOI":"10.1038\/cddis.2016.305","article-title":"Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition","volume":"7","author":"Zhang","year":"2016","journal-title":"Cell Death Dis."},{"issue":"13","key":"10.1016\/j.bcp.2026.118532_b1095","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b1100","article-title":"A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors","volume":"9","author":"Xu","year":"2022","journal-title":"Adv Sci (weinh)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b1105","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","article-title":"CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer","volume":"159","author":"Chipumuro","year":"2014","journal-title":"Cell"},{"issue":"7510","key":"10.1016\/j.bcp.2026.118532_b1110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature13473","article-title":"Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles","volume":"511","author":"Walz","year":"2014","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.bcp.2026.118532_b1115","doi-asserted-by":"crossref","first-page":"E6409","DOI":"10.1073\/pnas.1613601113","article-title":"Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma","volume":"113","author":"McFadden","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b1125","first-page":"193","article-title":"X-ray structures of Myc-Max and Mad-Max recognizing DNA","volume":"112","author":"Nair","year":"2003","journal-title":"Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors, Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.bcp.2026.118532_b1135","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-Myc-Targeting PROTAC based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-negative Breast Cancer","volume":"145","author":"Li","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b1140","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-07-0005","article-title":"Improved low molecular weight Myc-Max inhibitors","volume":"6","author":"Wang","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b1145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.chembiol.2008.09.011","article-title":"Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules","volume":"15","author":"Follis","year":"2008","journal-title":"Chem. Biol."},{"issue":"21","key":"10.1016\/j.bcp.2026.118532_b1150","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1021\/ja900616b","article-title":"Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc","volume":"131","author":"Hammoudeh","year":"2009","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/jpet.110.170555","article-title":"In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc\/Max dimerization","volume":"335","author":"Clausen","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b1160","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1021\/jm501440q","article-title":"Perturbation of the c-Myc-Max protein-protein interaction via synthetic alpha-helix mimetics","volume":"58","author":"Jung","year":"2015","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b1165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-008-0774-y","article-title":"Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice","volume":"63","author":"Guo","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"26","key":"10.1016\/j.bcp.2026.118532_b1170","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"Antitumor effect of Anti-c-Myc Aptamer-based PROTAC for Degradation of the c-Myc Protein","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci (weinh)"},{"issue":"2","key":"10.1016\/j.bcp.2026.118532_b1175","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1021\/acs.jmedchem.2c01557","article-title":"Inducible Degradation of Oncogenic Nucleolin using an Aptamer-based PROTAC","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118532_b1180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtn.2022.09.008","article-title":"Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bcp.2026.118532_b1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116978","article-title":"Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma","volume":"280","author":"Ai","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"48","key":"10.1016\/j.bcp.2026.118532_b1190","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202508518","article-title":"Sulfinyl Aziridines as Stereoselective Covalent Destabilizing Degraders of the Oncogenic Transcription factor MYC","volume":"64","author":"Rosen","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b1195","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0092-8674(91)90100-D","article-title":"Human D-type cyclin","volume":"65","author":"Xiong","year":"1991","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b1200","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(91)90101-4","article-title":"Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle","volume":"65","author":"Matsushime","year":"1991","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1205","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0092-8674(92)90518-H","article-title":"D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA","volume":"71","author":"Xiong","year":"1992","journal-title":"Cell"},{"issue":"49","key":"10.1016\/j.bcp.2026.118532_b1210","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"6841","key":"10.1016\/j.bcp.2026.118532_b1215","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/35082500","article-title":"Specific protection against breast cancers by cyclin D1 ablation","volume":"411","author":"Yu","year":"2001","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bcp.2026.118532_b1220","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1101\/gad.9.19.2364","article-title":"Mice lacking cyclin D1 are small and show defects in eye and mammary gland development","volume":"9","author":"Fantl","year":"1995","journal-title":"Genes Dev."},{"issue":"33","key":"10.1016\/j.bcp.2026.118532_b1225","doi-asserted-by":"crossref","first-page":"29742","DOI":"10.1021\/jacs.5c04918","article-title":"DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1-CDK4\/6 complex Protein Degradation","volume":"147","author":"Zheng","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"17","key":"10.1016\/j.bcp.2026.118532_b1230","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1021\/acs.jmedchem.9b00919","article-title":"Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1\/Bcl-2 Derived from Nonselective Target Binding Ligands","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"issue":"98","key":"10.1016\/j.bcp.2026.118532_b1235","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1039\/C9CC07217A","article-title":"Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X(L)","volume":"55","author":"Zhang","year":"2019","journal-title":"Chem. Commun. (Camb)"},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b1240","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2024027117","article-title":"Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1250","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216-a bcl-xL-specific degrader is highly active against bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1255","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","article-title":"First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies","volume":"18","author":"Mahadevan","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118532_b1260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112186","article-title":"Discovery of PROTAC BCL-X(L) degraders as potent anticancer agents with low on-target platelet toxicity","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118532_b1265","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1039\/D5MD00119F","article-title":"Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting bcl-xL degrader","volume":"16","author":"Zhang","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1270","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41467-020-15838-0","article-title":"Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity","volume":"11","author":"He","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118532_b1275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112397","article-title":"Discovery of IAP-recruiting BCL-X(L) PROTACs as potent degraders across multiple cancer cell lines","volume":"199","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118532_b1280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117624","article-title":"Discovery of XZ338, a highly potent BCL-X(L) degrader","volume":"291","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2026.118532_b1285","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.7150\/thno.75421","article-title":"The PROTAC selectively degrading Bcl-x(L) represents a novel Hedgehog pathway inhibitor with capacity of combating resistance to Smoothened inhibitors while sparing bone growth","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"Pt 1","key":"10.1016\/j.bcp.2026.118532_b1290","article-title":"Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-x(L), display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity","volume":"230","author":"Zhang","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118532_b1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116731","article-title":"The PROTAC selectively degrading BCL-X(L) inhibits the growth of tumors and significantly synergizes with Paclitaxel","volume":"232","author":"Qiu","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1300","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43587-025-00811-7","article-title":"A BCL-xL\/BCL-2 PROTAC effectively clears senescent cells in the liver and reduces MASH-driven hepatocellular carcinoma in mice","volume":"5","author":"Yang","year":"2025","journal-title":"Nat. Aging"},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b1305","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1310","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2026.118532_b1315","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/acs.jmedchem.9b00455","article-title":"From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)","volume":"62","author":"Papatzimas","year":"2019","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b1320","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the 'high-hanging fruit'","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.bcp.2026.118532_b1330","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41573-020-0078-4","article-title":"Soluble ligands as drug targets","volume":"19","author":"Attwood","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2026.118532_b1340","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1345","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/acschembio.3c00645","article-title":"Targeted Extracellular Protein Degradation by Dendronized DNA Chimeras","volume":"19","author":"Zhu","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118532_b1350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112260","article-title":"Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview","volume":"194","author":"Mondal","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2026.118532_b1355","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/jm960871c","article-title":"Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits","volume":"40","author":"MacPherson","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118532_b1360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117027","article-title":"Development of hybrid aptamers-engineered PROTACs for degrading VEGF165 in both tumor- and vascular endothelial cells","volume":"281","author":"Feng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b1365","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118532_b1370","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in Signaling and Disease: beyond Discovery and Development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"50","key":"10.1016\/j.bcp.2026.118532_b1375","doi-asserted-by":"crossref","first-page":"31582","DOI":"10.1074\/jbc.272.50.31582","article-title":"Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165","volume":"272","author":"Soker","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118532_b1380","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/labinvest.3700258","article-title":"VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms","volume":"85","author":"Schoeffner","year":"2005","journal-title":"Lab. Invest."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b1385","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1023\/A:1006358220123","article-title":"Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors","volume":"18","author":"Schlaeppi","year":"1999","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.bcp.2026.118532_b1390","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118532_b1395","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as Therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1400","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2026.118532_b1405","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1217769","article-title":"Anti-nucleolin aptamer AS1411: an advancing therapeutic","volume":"10","author":"Van den Avont","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bcp.2026.118532_b1410","doi-asserted-by":"crossref","unstructured":"X. Fu, J. Li, X. Chen, H. Chen, Z. Wang, F. Qiu, D. Xie, J. Huang, S. Yue, C. Cao, Y. Liang, A. Lu, C. Liang, Repurposing AS1411 for constructing ANM-PROTACs, Cell Chem Biol 31(7) (2024) 1290-1304 e7.","DOI":"10.1016\/j.chembiol.2024.03.011"},{"key":"10.1016\/j.bcp.2026.118532_b1415","doi-asserted-by":"crossref","first-page":"12793","DOI":"10.1038\/srep12793","article-title":"HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response","volume":"5","author":"Lim","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118532_b1420","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/molecules15010215","article-title":"Screening and improvement of an anti-VEGF DNA aptamer","volume":"15","author":"Nonaka","year":"2010","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.bcp.2026.118532_b1425","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.7150\/thno.98467","article-title":"Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis","volume":"14","author":"Zhou","year":"2024","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bcp.2026.118532_b1430","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.bcp.2026.118532_b1435","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118532_b1440","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/anie.201914396","article-title":"Structure-based Design of a Macrocyclic PROTAC","volume":"59","author":"Testa","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"47","key":"10.1016\/j.bcp.2026.118532_b1445","doi-asserted-by":"crossref","first-page":"17233","DOI":"10.1021\/ja9051735","article-title":"Creating protein affinity reagents by combining peptide ligands on synthetic DNA scaffolds","volume":"131","author":"Williams","year":"2009","journal-title":"J. Am. Chem. Soc."},{"issue":"18","key":"10.1016\/j.bcp.2026.118532_b1450","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1002\/anie.201007593","article-title":"DNA as a molecular ruler: interrogation of a tandem SH2 domain with self-assembled, bivalent DNA-peptide complexes","volume":"50","author":"Eberhard","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"3","key":"10.1016\/j.bcp.2026.118532_b1455","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination factor GSPT1 is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:08:17Z","timestamp":1792138097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":291,"alternative-id":["S0006295226008749"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118532","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein degraders targeting JAK\/STAT3 signaling pathway are emerging therapeutic modalities for human cancers","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118532"}}